hydrazine has been researched along with Hematologic Diseases in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (30.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 5 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azizian, NG; Li, Y | 1 |
| Amberg, S; Bokemeyer, C; Christine Wilke, A; Chromik, J; Deppermann, U; Fiedler, W; Ganser, A; Heuser, M; Janning, M; Kebenko, M; Kranich, AL; Modemann, F; Schlipfenbacher, V; Serve, H; Theile, S; Thol, F | 1 |
| Alonso, L; Benitez-Carabante, MI; Diaz-de-Heredia, C; Oliveras, M; Renedo, B; Uria-Oficialdegui, ML | 1 |
| Anderson, LD; Arazy, M; Auner, HW; Badros, A; Bahlis, NJ; Benjamin, R; Cavo, M; Chai, Y; Delimpasi, S; Dimopoulos, MA; Dolai, TK; Doronin, V; Facon, T; Garg, M; Gavriatopoulou, M; Grosicki, S; Hajek, R; Jagannath, S; Kauffman, MG; Kriachok, I; Leleu, X; Levy, M; Mateos, MV; Moreau, P; Pour, L; Pylypenko, H; Quach, H; Richardson, PG; Shacham, S; Shah, J; Simonova, M; Sinha, DK; Spicka, I; Stevens, DA; Usenko, G; Venner, CP | 1 |
| Bacigalupo, A; Busca, A; Chiusolo, P; Giammarco, S; Laurenti, L; Martino, M; Metafuni, E; Risitano, A; Sica, S; Sorá, F; Vallejo, C | 1 |
| Pathak, S; Roth, M; Steidl, U; Verma, A | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| GOLDBERG, LI | 1 |
| Clément, F | 1 |
| Kühböck, J; Mannheimer, E | 1 |
4 review(s) available for hydrazine and Hematologic Diseases
| Article | Year |
|---|---|
XPO1-dependent nuclear export as a target for cancer therapy.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Exportin 1 Protein; Forecasting; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hydrazines; Karyopherins; Molecular Targeted Therapy; Neoplasm Proteins; Receptors, Cytoplasmic and Nuclear; RNA, Neoplasm; Triazoles | 2020 |
Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.
Topics: Antineoplastic Agents; Benzoates; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Hematologic Diseases; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Thrombopoietin; Thrombocytopenia | 2013 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
MONOAMINE OXIDASE INHIBITORS. ADVERSE REACTIONS AND POSSIBLE MECHANISMS.
Topics: Amphetamine; Amphetamines; Chemical and Drug Induced Liver Injury; Headache; Hematologic Diseases; Hepatitis; Hydrazines; Hypertension; Hypotension; Hypotension, Orthostatic; Isocarboxazid; Monoamine Oxidase Inhibitors; Nialamide; Optic Atrophy; Pargyline; Phenelzine; Sympathomimetics; Toxicology; Tranylcypromine | 1964 |
1 trial(s) available for hydrazine and Hematologic Diseases
| Article | Year |
|---|---|
A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Progression-Free Survival; Recurrence; Salvage Therapy; Triazoles | 2020 |
5 other study(ies) available for hydrazine and Hematologic Diseases
| Article | Year |
|---|---|
Use of eltrombopag for the treatment of poor graft function after hematopoietic stem cell transplantation in children.
Topics: Adolescent; Benzoates; Blood Cell Count; Child; Female; Hematologic Agents; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Treatment Outcome | 2021 |
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Administration Schedule; Female; Frailty; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hydrazines; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Nervous System Diseases; Progression-Free Survival; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index; Triazoles | 2021 |
Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study.
Topics: Adult; Aged; Benzoates; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Italy; Male; Middle Aged; Primary Graft Dysfunction; Pyrazoles; Retrospective Studies; Transplantation, Homologous; Treatment Outcome; Young Adult | 2021 |
[Therapy of malignant hemopathies].
Topics: Female; Hematologic Diseases; Humans; Hydrazines; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Multiple Myeloma; Prednisone | 1966 |
[Recent cytostatic therapy in hemoblastosis and malignant tumors].
Topics: Antineoplastic Agents; Hematologic Diseases; Humans; Hydrazines; Neoplasms | 1966 |